Market Research Logo

Global Solid Tumors Drugs Market 2016-2020

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Types of solid tumors
    • Markers used for diagnosis of solid tumors
      • Table Markers used for types of solid tumors
  • Cost analysis
    • Table Annual treatment cost per patient for solid tumor drugs 2014
    • Table Average cost of surgeries associated with solid tumors 2014 ($)
    • Table Average cost of chemotherapy 2014 ($)
    • Table Average cost of radiation therapy 2014 ($)
  • Pipeline portfolio
    • Table Phase III pipeline molecules for solid tumors
    • Table Phase II pipeline molecules for solid tumors
    • Table Phase I pipeline molecules for solid tumors
    • Table Pre-clinical pipeline molecules for solid tumors
    • Table Pipeline share of solid tumors drugs 2015
    • Anticipated number of products with single and multiple indications by 2020
      • Table Near-launch immuno-oncology pipeline assets 2020
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global solid tumors market 2015-2020 ($ billions)
      • Table Factors influencing global solid tumors drugs market 2015
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by molecule type
    • Table Segmentation of global solid tumors drugs market by type of molecules 2015
    • Small molecules
    • Biologics
  • Market segmentation by type of therapy
    • Chemotherapy
    • Hormone therapy
    • Targeted therapy
    • Immunotherapy
  • Market segmentation by disease
    • Table Market segmentation by disease
    • Table Global solid tumors drugs market: Segmentation by disease 2015
    • Table Global solid tumors drugs market: YoY revenue and growth based on drug class 2015-2020 ($billions)
    • Global breast cancer drugs market
      • Table Stages of breast cancer based on tumor size and extent of metastasis
      • Table Classification of breast cancer based on genetic makeup of tumor cells
      • Table Treatment regimen for breast cancer
      • Table Product offerings for breast cancer drugs market
      • Table Global breast cancer drugs market 2015-2020 ($ billions)
    • Global NHL drugs market
      • Table Product offerings for global NHL drugs market
      • Table Global NHL drugs market 2015-2020 ($ billions)
    • Global colorectal cancer drugs market
      • Table Product offerings for global colorectal cancer drugs market
      • Table Global colorectal cancer drugs market 2015-2020 ($ billions)
    • Global NSCLC drugs market
      • Table Products offerings for global NSCLC drugs market
      • Table Global NSCLC drugs market 2015-2020 ($ billions)
    • Global prostate cancer drugs market
      • Table Product offerings for global prostate cancer drugs market
      • Table Global prostate cancer drugs market 2015-2020 ($ billions)
    • Global kidney cancer drugs market
      • Table Product offerings for global kidney cancer drugs market
      • Table Global kidney cancer drugs market 2015-2020 ($ billions)
    • Global retinoblastoma drugs market
      • Table Product offerings for global retinoblastoma drugs market
      • Table Global retinoblastoma drugs market 2015-2020 ($ billions)
    • Global cervical cancer market
      • Table Product offerings for global cervical cancer market
      • Table Global cervical cancer market 2015-2020 ($ billions)
    • Global melanoma drugs market
      • Table Product offerings for global melanoma drugs market
      • Table Global melanoma drugs market 2015-2020 ($ billions)
    • Global gastric cancer drugs market
      • Table Products offerings for global gastric cancer drugs market
      • Table Global gastric cancer drugs market 2015-2020 ($ billions)
    • Global pancreatic cancer drugs market
      • Table Products offerings for global pancreatic cancer drugs market
      • Table Global pancreatic cancer drugs market 2015-2020 ($ billions)
    • Global ovarian cancer drugs market
      • Table Products offerings for global ovarian cancer drugs market
      • Table Global ovarian cancer drugs market 2015-2020 ($ billions)
    • Global liver cancer drugs market
      • Table Product offerings for global liver cancer drugs market
      • Table Global liver cancer drugs market 2015-2020 ($ billions)
    • Global HL drugs market
      • Table Products offerings for global HL drugs market
      • Table Global HL drugs market 2015-2020 ($ millions)
    • Global glioblastoma multiforme drugs market
      • Table Products offerings for global glioblastoma multiforme drugs market
      • Table Global glioblastoma multiforme drugs market 2015-2020 ($ millions)
  • Geographical segmentation
    • Table Global solid tumors drugs market by geography 2015
    • Table Global solid tumors drugs market revenue by geography 2015-2020 ($ billions)
    • Table Global solid tumors drugs market revenue by geography 2015-2020
    • Solid tumors drugs market in Americas
      • Table Solid tumors drugs market in Americas 2015-2020 ($ billions)
    • Solid tumors drugs market in EMEA
      • Table Solid tumors drugs market in EMEA 2015-2020 ($ billions)
    • Solid tumors drugs market in APAC
      • Table Solid tumors drugs market in APAC 2015-2020 ($ billions)
      • Table Global solid tumors drugs market: YoY revenue and growth based on geography 2015-2020 ($billions)
  • Market drivers
    • Patient assistance programs
    • Exposure to risk factors
    • Provision for rare diseases
    • Promising pipeline
    • Increase in prevalence of solid tumors
      • Table Global incidence of solid tumor types 2015
      • Table Global mortality of solid tumor types 2015
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiration of top-selling drugs
      • Table Patent expiries of major cancer monoclonal antibodies by 2020
    • Poor diagnosis and screening
    • High cost of drugs
      • Table Average cost comparison of Herceptin 2014
    • Availability of chemotherapy and off-label drugs
    • Stringent regulations
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in cancer awareness
    • Emergence of targeted and combination therapies
      • Table Expected combination regimen launches in oncology
    • Emergence of biosimilars
    • Joint ventures and partnerships for R&D
    • Increase in use of brachytherapy
  • Vendor landscape
    • Competitive scenario
      • Table YoY Sales comparison of top drugs 2013-2015 ($ billions)
    • Market share analysis 2015
      • Table Ranking of major vendors for global solid tumors drugs market
      • Table Market share analysis of global solid tumors drugs market 2015
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of bThera/Rituxan (oncology indications) 2013-2015 ($ billions)
      • Table MabThera/Rituxan geographic segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
      • Table F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($millions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Kadycla 2015
      • Table F. Hoffmann-La Roche: Revenue generated from net product sales of Tarceva 2013-2015 ($billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Tarceva 2015
      • Table F. Hoffmann-La Roche: Key takeaways
    • Novartis
      • Table Novartis: YoY revenue and growth rate of Gleevec 2013-2015 ($ billions)
      • Table Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
      • Table Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
      • Table Novartis: Key takeaways
    • Celgene
      • Table Celgene: YoY revenue and growth rate of Revlimid 2013-2015 ($ billions)
      • Table Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
      • Table Celgene: YoY revenue and growth rate of Istodax 2013-2015 ($ millions)
      • Table Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
      • Table Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
      • Table Celgene: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: YoY revenue comparison of Zytiga 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue comparison of Velcade 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue comparison of Imbruvica 2014-2015 ($ millions)
      • Table Key takeaways
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Sutent 2013-2015 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
      • Table Pfizer: YoY revenue and growth rate of Inlyta 2013-2015 ($ millions)
      • Table Key takeaways
    • BMS
      • Table BMS: YoY revenue and growth rate of Erbitux 2013-2015 ($ millions)
      • Table BMS: YoY revenue and growth rate of Sprycel 2013-2015 ($ billions)
      • Table Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Global Solid Tumors Drugs Market 2016-2020

About the Solid Tumors Drugs Market

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

Technavio’s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • Novartis
  • Celgene
  • Johnson & Johnson
  • Pfizer
  • BMS
Other prominent vendors
  • AbbVie
  • AbGenomics
  • ADC Therapeutics
  • Advantagene
  • Agensys
  • Almac Group
  • Ambrx
  • Argos Therapeutics
  • Array BioPharma
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Boehringer Ingelheim
  • Boston Biomedical
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • Cold Genesys
  • CTI BioPharma
  • Daiichi Sankyo
  • DNAtrix
  • Ds-Pharma
  • Eleison Pharmaceuticals
  • Eli Lilly
  • Endo Pharmaceuticals
  • Formation Biologics
  • Fortress Biotech
  • Genmab
  • GSK
  • Immatics Biotechnologies
  • Immunogen
  • Immunomedics
  • Intas Pharmaceuticals
  • Kairos Therapeutics
  • Kyowa Hakko Kirin
  • MedImmune
  • Merck
  • Mersana Therapeutics
  • Morphotek
  • Neovii Biotech
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Oxford Biotherapeutics
  • Peregrine Pharmaceuticals
  • Polaris Pharmaceuticals
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Stemcentrx
  • Synthon Biopharmaceuticals
  • TG Therapeutics
  • XBiotech
Market driver
  • Exposure to risk factors
  • For a full, detailed list, view our report
Market challenge
  • Patent expiration of top-selling drugs
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Solid Tumors Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global solid tumors drugs market: F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS.

Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, and XBiotech.

Commenting on the report, an analyst from Technavio’s team said: “A trend which is helping to boost market growth is the emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed to treat solid tumors. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2, wherein drugs such as Kadcyla and Herceptin are administered as monotherapies or in combination. Targeting multiple pathways are known to reduce the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating solid tumors.”

According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity.

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer.

Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs. The patent rights of most cancer drugs either have expired or are nearing their expiry date. As a result, inexpensive generic drugs are being introduced in the market. These drugs may increase the competition in the market, eventually reducing the price of key drugs. Also, patent expiries often result in loss of market exclusivity, decreasing the sales of the branded product.

Companies Mentioned

F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, BMS, AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, XBiotech.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;